Although the product pipeline for vaccines and therapeutics targeting COVID-19 is top of mind right now, investors are also keeping a close eye on companies involved in the development of medicines targeting cancer and the central nervous system. According to financings tracked by BioWorld and deals and grants logged in Cortellis, the therapeutic areas of cancer, neurology and psychiatric attracted the highest amounts of investments last year with a collective $101.9 billion and $27.5 billion raised, respectively.

Although the COVID-19 pandemic has decimated the economy and played havoc with the financial markets, there are promising signs that investors are slowly returning as infection curves begin to flatten thanks to social distancing measures. There is no doubt that they are showing confidence in those leading biopharmaceutical companies who they believe hold the keys to unlocking cures for the deadly infection. In addition, amid the intense activity related to COVID-19 research and development, the FDA did take some time to approve several new medicines, reinforcing the fact that innovation has not been completely throttled by the industry’s focus on the pandemic.

Regulatory decisions affecting biopharma products in development, including: Abbvie, Agenus, Algernon, Alnylam, Anheart, Astrazeneca, Aurinia, Bellerophon, Biocryst, Bluebird, Can-Fite, Cansino, Cstone, Cytodyn, Cytokinetics, Dicerna, Eiger, Eisai, Eli Lilly, Exelixis, Genentech, Gilead Sciences, Hansoh, Helsinn, Humanigen, Immunomic, Immutep, Inmed, Intelgenx, Intercept, Intrabio, Janssen, Jazz, Kadmon, Kempharm, Lupin, Mallinckrodt, Mylan, Neuren, Newron, Nicox, Novartis, Orchard, Orion, Paratek, Pfizer, Pharming, Pharnext, Recordati, Sage, Sanofi, Seelos, Spero, Synairgen, Takeda, Teva, Trevena, Valneva, Virometix, Zai Lab, Zealand, Zydus Cadila.

In order to redirect health care resources and protect patients during the COVID-19 pandemic, many drug companies have paused enrollment in some or all of their ongoing clinical trials.